Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

Blood (2024) 143 (20): 2053–2058.

https://doi.org/10.1182/blood.2023021184

Published: 2024

Includes: Supplemental data

Journal Articles

Multicenter Pilot Trial of Intrathecal Liposomal Cytarabine Combined with FAB Chemoimmunotherapy with Reduced Doxorubicin in CAYA with Mature De-Novo B-NHL

Anthony N. Audino, Stanton Goldman, Matthew J. Barth, Jessica Hochberg, Ana C. Xavier, Bruce Shiramizu, Qiuhu Shi, Lauren Harrison, Jackie Basso, Javier Oesterheld, Kenneth Matthew Heym, Richard A. Drachtman, Paul Harker-Murray, Sherrie L. Perkins, Rodney R. Miles, Mitchell S. Cairo

Blood (2023) 142 (Supplement 1): 1727.

https://doi.org/10.1182/blood-2023-181756

Published: 2023

Journal Articles

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults

Paul Harker-Murray, Christine Mauz-Körholz, Thierry Leblanc, Maurizio Mascarin, Gérard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Loredana Amoroso, Salvatore Buffardi, Charlotte Rigaud, Bradford S. Hoppe, Julie Lisano, Stephen Francis, Mariana Sacchi, Peter D. Cole, Richard A. Drachtman, Kara M. Kelly, Stephen Daw

Blood (2023) 141 (17): 2075–2084.

https://doi.org/10.1182/blood.2022017118

Published: 2023

Includes: Supplemental data

Journal Articles

Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231

Blood (2022) 140 (Supplement 1): 6387–6389.

https://doi.org/10.1182/blood-2022-159694

Published: 2022

Journal Articles

Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 3487.

https://doi.org/10.1182/blood-2021-151837

Published: 2021

Journal Articles

Brentuximab Vedotin As Consolidation Therapy Following Autologous Stem Cell Transplantation in Children and Adolescents with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Center Retrospective Analysis

Christopher J. Forlenza, Jaclyn Rosenzweig, Audrey Mauguen, Ilia Buhtoiarov, Branko Cuglievan, Hema Dave, Rebecca J Deyell, Jaime Flerlage, Anna Franklin, Jennifer Krajewski, Kasey J Leger, Lianna Marks, Robin Norris, Martha Pacheco, Faye Willen, Adam Paul Yan, Paul Harker-Murray, Lisa Giulino Roth

Blood (2021) 138 (Supplement 1): 2465.

https://doi.org/10.1182/blood-2021-151808

Published: 2021

Journal Articles

Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-134730

Published: 2020

Journal Articles

Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL)

Jessica C. Hochberg, MD, Stanton Goldman, MD, Matthew J. Barth, MD, Qiuhu Shi, PhD, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Jackie Basso, Yaya Chu, PhD, Humayun Islam, Perry Gerard, MD MBA, FACR, Javier Oesterheld, MD, Kenneth Matthew Heym, MD, Ivan I. Kirov, MD, Richard A. Drachtman, MD, Paul Harker-Murray, MD PhD, Sherrie L. Perkins, MD PhD, Rodney R. Miles, MD PhD, Bruce Shiramizu, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-139464

Published: 2020

Journal Articles

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

Paul Harker-Murray, MD PhD, Thierry Leblanc, MD, Maurizio Mascarin, Christine Mauz-Körholz, Gerard Michel, MD, Stacy Cooper, MD, Auke Beishuizen, MD PhD, Kasey J. Leger, MD MSc, Alberto Garaventa, Salvatore Buffardi, MD, Laurence Brugieres, MD, Kara M. Kelly, MD, Peter D. Cole, MD, Richard A. Drachtman, Faith Galderisi, DO, Mariana Sacchi, MD, Ying-Ming Jou, Stephen Daw

Blood (2018) 132 (Supplement 1): 927.

https://doi.org/10.1182/blood-2018-99-111279

Published: 2018

Journal Articles

Open-Label Bendamustine for Pediatric Patients with Relapsed or Refractory Acute Leukemia: Safety and Efficacy Outcomes,

Christopher Fraser, MD, Patrick A. Brown, MD, Gail C. Megason, MD, Hyo Seop Ahn, MD, Bin Cho, MD, Ivan I. Kirov, MD, Lawrence S. Frankel, MD, Richard Aplenc, MD, MSCE, Debra M. Bensen-Kennedy, MD, Mihaela C. Munteanu, MS, Jennifer Weaver, Paul Harker-Murray, MD, PhD

Blood (2011) 118 (21): 3602.

https://doi.org/10.1182/blood.V118.21.3602.3602

Published: 2011

Journal Articles

Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells

Keli L. Hippen, Paul Harker-Murray, Stephen B. Porter, Sarah C. Merkel, Aryel Londer, Dawn K. Taylor, Megan Bina, Angela Panoskaltsis-Mortari, Pablo Rubinstein, Nico Van Rooijen, Tatiana N. Golovina, Megan M. Suhoski, Jeffrey S. Miller, John E. Wagner, Carl H. June, James L. Riley, Bruce R. Blazar

Blood (2008) 112 (7): 2847–2857.

https://doi.org/10.1182/blood-2008-01-132951

Published: 2008

Includes: Supplemental data

Journal Articles

Hematopoietic Cell Transplantation as Therapy for Pediatric Patients with Isolated CNS Relapse.

Paul Harker-Murray, MD, PhD, Jakub Tolar, MD, PhD, Ye Tan, MS, Margaret L. MacMillan, MD, John Wagner, MD, Paul J. Orchard, MD

Blood (2005) 106 (11): 2745.

https://doi.org/10.1182/blood.V106.11.2745.2745

Published: 2005

NARROW

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

Multicenter Pilot Trial of Intrathecal Liposomal Cytarabine Combined with FAB Chemoimmunotherapy with Reduced Doxorubicin in CAYA with Mature De-Novo B-NHL

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults

Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231

Brentuximab Vedotin As Consolidation Therapy Following Autologous Stem Cell Transplantation in Children and Adolescents with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Center Retrospective Analysis

Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231

Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL)

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

Open-Label Bendamustine for Pediatric Patients with Relapsed or Refractory Acute Leukemia: Safety and Efficacy Outcomes,

Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells

Hematopoietic Cell Transplantation as Therapy for Pediatric Patients with Isolated CNS Relapse.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only